24 Apr 2020 07:00
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Notice of Results
24 April 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, will be announcing its half year results for the six months ended 31 January 2020 on Wednesday 29 April 2020.
- ENDS -
For further information, please contact:
C4X Discovery Holdings | |
Mo Noonan, Communications | +44 (0)787 6444977 |
Panmure Gordon (UK) Limited (NOMAD and Broker) | |
Freddy Crossley, Emma Earl (Corporate Finance) | +44 (0)20 7886 2500 |
James Stearns (Corporate Broking) | |
C4X Discovery Media - Consilium Strategic Communications | |
Mary-Jane Elliott, Chris Gardner, Matthew Neal | +44 (0)203 709 5700 |
Notes to Editors:
About C4X Discovery
C4X Discovery (C4XD) aims to create the world's most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m.
C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.
For additional information please go to: www.c4xdiscovery.com
C4XD.L (C4XD)